Stimulant supply shifts

When the Food and Drug Administration posted an Adderall shortage in October 2022, many U.S. children did not stop stimulant treatment; they switched drugs instead. (fda.gov) (pmc.ncbi.nlm.nih.gov) A Pediatrics study using IQVIA prescription data, which covers 92% of U.S. prescriptions, tracked stimulant dispensing for children ages 5 to 17 from 2017 through 2023. It found no statistically significant drop in overall stimulant dispensing after October 2022, even as Adderall immediate-release dispensing fell. (pmc.ncbi.nlm.nih.gov) The clearest shift was inside the stimulant market: immediate-release mixed amphetamine salts, the generic form behind Adderall IR, dropped in October 2022, while dexmethylphenidate dispensing rose. The authors said the decline in one product was offset by increases in other stimulants. (pmc.ncbi.nlm.nih.gov) (publications.aap.org) Stimulants are the main drug treatment for attention-deficit/hyperactivity disorder, and the condition has a lifetime prevalence of 11.4% among U.S. children, the study said. That made a shortage of one of the best-known products a supply problem for routine care, not a niche disruption. (pmc.ncbi.nlm.nih.gov) The shortage began when the Food and Drug Administration listed immediate-release amphetamine mixed salts on its drug shortage site on October 12, 2022. The agency said Teva was dealing with intermittent manufacturing delays and other manufacturers could not fully cover U.S. demand. (fda.gov) Federal regulators also pointed prescribers and patients to alternatives, including extended-release amphetamine mixed salts. That guidance matched what showed up in the dispensing data: treatment moved sideways to substitute products rather than disappearing. (fda.gov) (pmc.ncbi.nlm.nih.gov) Other research has framed the same episode as a broader supply-chain problem across ADHD medicines, not a single-brand failure. A March 2026 JAMA Health Forum analysis plotted the October 2022 shortage against changes in amphetamine, lisdexamfetamine, and methylphenidate distribution and highlighted how supply and demand shifted across stimulant classes. (jamanetwork.com) The pressure did not stay confined to the U.S. Australia’s Therapeutic Goods Administration said on April 21, 2026 that shortages of most methylphenidate modified-release products had resolved, after a global shortage that started in late 2024. Concerta and Ritalin LA supply had largely stabilized, while Rubifen LA shortages were expected to resolve by the end of June 2026. (tga.gov.au) The result is a medication market that kept children on treatment by redistributing demand across brands, doses, and stimulant classes. The shortage changed what was dispensed more than whether stimulants were dispensed at all. (pmc.ncbi.nlm.nih.gov)